Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome With Partial Least Squares Discriminant Analysis: Relevance of Blood Extracellular Vesicles. — CFSMEATLAS
Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome With Partial Least Squares Discriminant Analysis: Relevance of Blood Extracellular Vesicles.
González-Cebrián, Alba, Almenar-Pérez, Eloy, Xu, Jiabao et al. · Frontiers in medicine · 2022 · DOI
Quick Summary
Researchers tested whether tiny particles called extracellular vesicles in blood could help diagnose ME/CFS. They analyzed various substances in blood from patients and healthy controls using a computer analysis method. The study found that certain features of these blood particles, combined with other markers, could potentially identify ME/CFS, though more testing is needed to confirm this works reliably in larger groups.
Why It Matters
This research provides a potential diagnostic pathway for ME/CFS, a disease currently diagnosed only by clinical criteria without biomarkers. Identifying blood-based markers could enable earlier diagnosis, help distinguish ME/CFS from other conditions, and open doors for monitoring disease progression and treatment response. The findings suggest extracellular vesicles carry disease-specific information relevant to ME/CFS pathophysiology.
Observed Findings
Four extracellular vesicle features (size and proteinase K-sensitive z-values) emerged as discriminant variables among the top 32 regressors in the PLS-DA model.
Raman micro-spectroscopic analysis identified carotenoid peaks as a potential ME/CFS fingerprint, possibly associated with erythrocyte deficiencies.
A refined model combining Raman-selected PBMC miRNAs achieved perfect classification (AUC=1) of subjects.
Standalone Raman spectroscopy showed limited diagnostic power with AUC=0.7067.
Extracellular vesicles demonstrated disease-relevant structural and compositional differences between ME/CFS patients and controls.
Inferred Conclusions
Blood extracellular vesicles carry diagnostically relevant information for ME/CFS and warrant further investigation as biomarker sources.
A multimodal biomarker approach combining EV characteristics, miRNA profiles, and spectroscopic data may improve diagnostic discrimination.
Carotenoid deficiency in extracellular vesicles may reflect erythrocyte dysfunction in ME/CFS.
Further research in expanded patient cohorts is necessary before clinical implementation of these biomarkers.
Remaining Questions
Will the PLS-DA model and refined biomarker panel replicate in independent, larger patient cohorts from different geographic regions?
What This Study Does Not Prove
This study does not establish that extracellular vesicles cause ME/CFS or explain the mechanisms underlying the disease. The perfect classification achieved (AUC=1) in the refined model needs validation in independent populations—this single study cannot confirm clinical utility. The small sample size and retrospective design mean findings may not generalize to broader patient populations or different clinical settings.